Nan Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nan Yan has a total of 216 co-authors. Here are the top co-authors by number of shared publications:
- Kun Yang
Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA
26 shared publications - Devon Jeltema
Department of Immunology, University of Texas Southwestern Medical Center
16 shared publications - Cong Xing
Department of Immunology, University of Texas Southwestern Medical Center
15 shared publications - Nicole Dobbs
University of Texas Southwestern Medical Center 1 Department of Immunology Dallas, TX
15 shared publications - Xintao Tu
Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA
14 shared publications - Kennady Knox
Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA
13 shared publications
Latest Publications
- Open Access
- 4 March 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (10)
PARP7 protects the lung epithelial barrier from diverse environmental threats
Poly-ADP-ribose polymerase (PARP) family proteins are involved in a wide range of cellular processes. Several PARPs are targeted by inhibitors as treatments for cancer based on their biochemical functions; however, the physiological functions of most PARPs and the potential adverse effects of PARP inhibition are unknown. Here, we show that PARP7 is important for lung physiology. Loss of PARP7 in mice increases susceptibility to chemically induced diffuse alveolar hemorrhaging (DAH) and pristane-induced lupus. Single-nucleus RNA-seq reveals that PARP7 is selectively expressed in alveolar type I cells and PARP7 loss increases immune cell infiltration within the lung, indicating a loss of epithelial barrier integrity. Further, PARP7 inhibition in human bronchial epithelial cells in air–liquid interface culture leads to increased barrier permeability after cigarette smoke challenge or bacterial infection. Mechanistically, we show that PARP7 target, aryl hydrocarbon receptor (AHR), mediates diverse cellular responses to cigarette smoke challenge, including loss of tight junction protein Occludin and increased expression of xenobiotic metabolizing genes and proinflammatory genes. Together, our study uncovers PARP7 as a key player in maintaining the epithelial barrier integrity within the lung, which may have important implications for pulmonary diseases and for guiding PARP7 inhibitor use in the clinic.
- 4 March 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (10)
Open AccessPARP7 protects the lung epithelial barrier from diverse environmental threats
Poly-ADP-ribose polymerase (PARP) family proteins are involved in a wide range of cellular processes. Several PARPs are targeted by inhibitors as treatments for cancer based on their biochemical functions; however, the physiological functions of most PARPs and the potential adverse effects of PARP inhibition are unknown. Here, we show that PARP7 is important for lung physiology. Loss of PARP7 in mice increases susceptibility to chemically induced diffuse alveolar hemorrhaging (DAH) and pristane-induced lupus. Single-nucleus RNA-seq reveals that PARP7 is selectively expressed in alveolar type I cells and PARP7 loss increases immune cell infiltration within the lung, indicating a loss of epithelial barrier integrity. Further, PARP7 inhibition in human bronchial epithelial cells in air–liquid interface culture leads to increased barrier permeability after cigarette smoke challenge or bacterial infection. Mechanistically, we show that PARP7 target, aryl hydrocarbon receptor (AHR), mediates diverse cellular responses to cigarette smoke challenge, including loss of tight junction protein Occludin and increased expression of xenobiotic metabolizing genes and proinflammatory genes. Together, our study uncovers PARP7 as a key player in maintaining the epithelial barrier integrity within the lung, which may have important implications for pulmonary diseases and for guiding PARP7 inhibitor use in the clinic.
- Top Cited Papers
- 15 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 391 (6782) , eadq9006
Nucleotide metabolic rewiring enables NLRP3 inflammasome hyperactivation in obesity
Obesity is a major disease risk factor due to obesity-associated hyperinflammation. We found that obesity induced Nod-like receptor pyrin domain–containing 3 (NLRP3) inflammasome hyperactivation and excessive interleukin (IL)–1β production in macrophages by disrupting SAM and HD domain–containing protein 1 (SAMHD1), a deoxynucleoside triphosphate (dNTP) hydrolase crucial for nucleotide balance. This caused aberrant accumulation of dNTPs, which can be transported into mitochondria, and initiated mitochondrial DNA (mtDNA) neosynthesis, which increased the presence of oxidized mtDNA and triggered NLRP3 hyperactivation. Deletion of SAMHD1 promoted NLRP3 hyperactivation in cells isolated from zebrafish, mice, and humans. SAMHD1-deficient mice showed elevated circulating IL-1β, insulin resistance, and metabolic dysfunction–associated steatohepatitis. Blocking dNTP mitochondrial transport prevented NLRP3 hyperactivation in macrophages from obese patients and SAMHD1-deficient mice. Our study revealed that obesity by inhibiting SAMHD1 rewired macrophage nucleotide metabolism, thereby triggering NLRP3 inflammasome hyperactivation to drive disease progression.
- 15 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 391 (6782) , eadq9006
Top Cited PapersNucleotide metabolic rewiring enables NLRP3 inflammasome hyperactivation in obesity
Obesity is a major disease risk factor due to obesity-associated hyperinflammation. We found that obesity induced Nod-like receptor pyrin domain–containing 3 (NLRP3) inflammasome hyperactivation and excessive interleukin (IL)–1β production in macrophages by disrupting SAM and HD domain–containing protein 1 (SAMHD1), a deoxynucleoside triphosphate (dNTP) hydrolase crucial for nucleotide balance. This caused aberrant accumulation of dNTPs, which can be transported into mitochondria, and initiated mitochondrial DNA (mtDNA) neosynthesis, which increased the presence of oxidized mtDNA and triggered NLRP3 hyperactivation. Deletion of SAMHD1 promoted NLRP3 hyperactivation in cells isolated from zebrafish, mice, and humans. SAMHD1-deficient mice showed elevated circulating IL-1β, insulin resistance, and metabolic dysfunction–associated steatohepatitis. Blocking dNTP mitochondrial transport prevented NLRP3 hyperactivation in macrophages from obese patients and SAMHD1-deficient mice. Our study revealed that obesity by inhibiting SAMHD1 rewired macrophage nucleotide metabolism, thereby triggering NLRP3 inflammasome hyperactivation to drive disease progression.
- Open Access
- 29 October 2025
- Published by Elsevier in Cell Reports
- Vol. 44 (11) , 116480
Autonomous STING signaling in Purkinje cells drives neurodegeneration independent of type I interferon
- 29 October 2025
- Published by Elsevier in Cell Reports
- Vol. 44 (11) , 116480
Open AccessAutonomous STING signaling in Purkinje cells drives neurodegeneration independent of type I interferon
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Data from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
Three-prime repair exonuclease 1 (TREX1) is the major DNase in mammalian cells that degrades cytosolic DNA to prevent activation of the cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway. Genotoxic stress, DNA damage, and radiotherapy induce TREX1 expression in cancer cells, allowing them to evade innate immune activation of type I IFN–mediated antitumor response. Therefore, targeting TREX1 could represent a potential approach to stimulate antitumor immunity. In this study, we conducted a high-throughput small-molecule inhibitor screen of TREX1 using a cell-free DNase assay. Compound 296 specifically inhibited TREX1 DNase activity at low micromolar concentrations, induced type I IFN signaling in cancer cells, and inhibited tumor growth in mice in an inteferon alpha/beta receptor (IFNAR)–dependent manner. Treatment with compound 296 also stimulated T-cell infiltration into tumors and synergized with immune checkpoint blockade. Trex1 knockout cancer cells elicited robust systemic antitumor immunity through tumor-intrinsic cGAS–STING activation and functioned as autologous cancer vaccines that protected against tumor challenge and metastasis. An inducible whole-body Trex1 knockout mouse model was established to simulate “on-demand” systemic TREX1 inactivation in adult mice. Sustained TREX1 loss suppressed a broad range of solid and metastatic tumors in adult mice without incurring severe immune toxicity, even when combined with immune checkpoint blockade, demonstrating the feasibility of an immune-safe therapeutic window. Together, these data demonstrate the antitumor efficacy and immune safety of multiple therapeutic modalities targeting TREX1, including targeting small-molecule inhibitors of TREX1 and employing TREX1 knockout tumor cells as an autologous cancer vaccine. These approaches should pave the way for developing TREX1-targeted cancer immunotherapies.Significance:Therapeutic modalities targeting TREX1 can activate cGAS-STING signaling and can be incorporated into autologous cancer vaccine designs to improve cancer treatment, supporting the potential of inactivating TREX1 to harness innate immunity.See related commentary by Hanks, p. 2778
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
Three-prime repair exonuclease 1 (TREX1) is the major DNase in mammalian cells that degrades cytosolic DNA to prevent activation of the cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway. Genotoxic stress, DNA damage, and radiotherapy induce TREX1 expression in cancer cells, allowing them to evade innate immune activation of type I IFN–mediated antitumor response. Therefore, targeting TREX1 could represent a potential approach to stimulate antitumor immunity. In this study, we conducted a high-throughput small-molecule inhibitor screen of TREX1 using a cell-free DNase assay. Compound 296 specifically inhibited TREX1 DNase activity at low micromolar concentrations, induced type I IFN signaling in cancer cells, and inhibited tumor growth in mice in an inteferon alpha/beta receptor (IFNAR)–dependent manner. Treatment with compound 296 also stimulated T-cell infiltration into tumors and synergized with immune checkpoint blockade. Trex1 knockout cancer cells elicited robust systemic antitumor immunity through tumor-intrinsic cGAS–STING activation and functioned as autologous cancer vaccines that protected against tumor challenge and metastasis. An inducible whole-body Trex1 knockout mouse model was established to simulate “on-demand” systemic TREX1 inactivation in adult mice. Sustained TREX1 loss suppressed a broad range of solid and metastatic tumors in adult mice without incurring severe immune toxicity, even when combined with immune checkpoint blockade, demonstrating the feasibility of an immune-safe therapeutic window. Together, these data demonstrate the antitumor efficacy and immune safety of multiple therapeutic modalities targeting TREX1, including targeting small-molecule inhibitors of TREX1 and employing TREX1 knockout tumor cells as an autologous cancer vaccine. These approaches should pave the way for developing TREX1-targeted cancer immunotherapies.Significance:Therapeutic modalities targeting TREX1 can activate cGAS-STING signaling and can be incorporated into autologous cancer vaccine designs to improve cancer treatment, supporting the potential of inactivating TREX1 to harness innate immunity.See related commentary by Hanks, p. 2778
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
RZ score, qAC50 and toxicity of 41 potent TREX1 inhibitors from the small-molecule inhibitor screen
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
RZ score, qAC50 and toxicity of 41 potent TREX1 inhibitors from the small-molecule inhibitor screen
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
TREX1 inhibitors suppress tumor progression in vivo
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
TREX1 inhibitors suppress tumor progression in vivo
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
Validation of Trex1-KO and double KO MC38 cells
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
Validation of Trex1-KO and double KO MC38 cells
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
In vivo toxicity analysis of inducible Trex1 KO in combination with anti-PD-1 immunotherapy
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
In vivo toxicity analysis of inducible Trex1 KO in combination with anti-PD-1 immunotherapy